• 1.

    Arnett DK, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 74:13761414.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Sharp Collaborative Group. Study of Heart and Kidney Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010; 160:785794.

    • Search Google Scholar
    • Export Citation
  • 3.

    Major RW, et al. Statins and cardiovascular primary prevention in CKD: a meta-analysis. Clin J Am Soc Nephrol 2015; 10:732739.

  • 4.

    Huang TM, et al. Effects of statin use in advanced chronic kidney disease patients. J Clin Med 2018; 7(9). doi: 10.3390/jcm7090285.

  • 5.

    Palmer SC, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 2012; 157:263275.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Herrington WG, et al. Impact of kidney function on the effects of LDL cholesterol lowering with statin-based regimens: A meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4:829839.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Reiss AB, et al. Cholesterol metabolism in non-diabetic chronic kidney disease. Am J Kidney Dis 2015; 66:10711082.

  • 8.

    Navaneethan SD, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; (2):CD007784.

    • Search Google Scholar
    • Export Citation
  • 9.

    Chung CM, et al. Effects of statin therapy on cerebrovascular and kidney outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. J Clin Lipidol 2017; 11:422431.e2.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Chang CH, et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis 2014; 232:224230.

    • Crossref
    • Search Google Scholar
    • Export Citation

STATIN DRUGS IN CKD AND ESRD: What Is Their Role?

  • 1 Mohammed Elsadany, MD, Yifeng Yang, MD, and Joseph Mattana, MD, are associated with St. Vincent’s Medical Center, Bridgeport, Connecticut, and the Quinnipiac University Frank H. Netter MD School of Medicine, North Haven, Connecticut. Sonali Gupta, MD, is associated with the University of Rochester, Rochester, New York.
Restricted access

Dyslipidemia has long been established as a traditional risk factor for cardiovascular disease in the general population. Dyslipidemia, characterized especially by elevated LDL and VLDL, is well known to be associated with higher atherosclerotic cardiovascular disease risk and is a large public health threat.

In patients with chronic kidney disease (CKD) and end stage renal disease (ESRD), cardiovascular disease is accelerated with an even larger impact, compared with the general population. Multiple variables are thought to contribute to this heightened propensity to and accelerated course of cardiovascular disease, including significant alterations in lipoprotein metabolism such as decreased HDL and increased

Save